If you typed Scientia Clinical Research into a search box, you are probably building a CRO shortlist. This article uses only what Scientia Clinical Research publishes (www.scientiaclinicalresearch.com.au · www.scientiaclinicalresearch.com.au/about-scientia · www.scientiaclinicalresearch.com.au/our-experience · www.scientiaclinicalresearch.com.au/sponsors) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.
What Scientia Clinical Research publishes
Scientia Clinical Research is a not-for-profit Phase 1 unit in Randwick, Sydney, incorporated in 2015 and based in the Bright Building on the Randwick health precinct. It has a long-term lease with South Eastern Sydney Local Health District and a service agreement with Prince of Wales Hospital for emergency support, and calls itself the only purpose-built first-in-human Phase 1 unit in central Sydney run as a not-for-profit. It claims 300+ studies completed, 24/7 participant monitoring, in-house ethics and start-up specialists, and experience in SAD/MAD, food-effect, drug-interaction, PK, biosimilar, vaccine and Phase 1 oncology studies. Its experience page lists "First In Human Medical device studies" among its capabilities, but we found no named device sponsor on the pages reviewed.
Scientia Clinical Research vs bioaccess®
| Dimension | Scientia Clinical Research | bioaccess® |
|---|---|---|
| Core focus | Not-for-profit drug Phase 1 unit; device FIH listed as a capability | First-in-human and early feasibility studies for medical devices |
| Geography | Australia | Latin America, since 2010 |
| Device FIH track record | No named device first-in-human study found on the public pages reviewed | Published case studies on bioaccessla.com |
| After the trial | See provider site | Live multi-country sanitary registration and in-country holder service |
Where each one fits
If you need a Sydney Phase 1 unit for a drug, a biologic, or a device study that can run under Phase 1 confinement, Scientia is a credible choice.
If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Scientia Clinical Research, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.
Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not Scientia Clinical Research features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.
Ready to compare a proposal? Request a first-in-human study proposal.
Competitor facts from the Scientia Clinical Research public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug 2026–Nov 2026). Claims are theirs. No invented sponsors, prices or contacts.